Using Bioengineered 3D Models To Replicate The Tumour Microenvironment In Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$339,658.00
Summary
The research will address the poor prognosis of patients with advanced prostate cancer bone metastasis by establishing a novel 3D bioengineered bone model containing high amounts of fat cells, where cancer cells can relocate. This approach will help identifying the impact of fat cells on cancer cell function, and help determine whether fat cells are legitimate therapeutic targets, ultimately assisting clinicians to select better therapies for prostate cancer bone metastasis.
Transcriptional Effectors Of Oncogenic ERK Signaling In Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$820,776.00
Summary
This project aims to unravel how one of the most frequently deregulated molecular pathways in colorectal cancer controls the expression of genes required for these tumours to grow and spread. We expect this work to uncover novel therapeutic targets to effectively inactivate this pathway and biomarkers to select patients most likely to benefit from existing therapies.
A Novel Protease And Growth Factor Regulated Signalling System In Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$856,743.00
Summary
Ovarian cancer is the leading cause of gynaecologic cancer death. Our project focuses on the role in ovarian cancer of a cellular receptor called CDCP1. We have previously shown that CDCP1 promotes growth and spread of ovarian tumours. Recently we have generated new data indicating that CDCP1’s activity is markedly increased by other proteins called proteases and growth factors. In this project we will define how these new pathways function, and if their blockade impedes ovarian cancer.
Breast cancers have diverse characteristics such as their response to treatment and their propensity to relapse. We know that the individual suit of oncogenic lesions probably influences diversity but the characteristics of the cell type from which the cancer arose probably also plays a part. This Application addresses this question and investigates a major new discovery made by the applicant that the ets transcription factor Elf5 plays a key role in specifying the diversity in breast cancer.
Targeting Homeobox Genes In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$658,739.00
Summary
Acute myeloid leukaemia (AML) is a common blood cancer with dire clinical prognosis due to a lack of targeted molecular therapies. In this proposal we will identify new ways of targeting transcription factor proteins that are overexpressed in AML and promote leukaemia by repressing normal cellular growth controls. This may lead to novel methods to target leukaemic stem cells to specifically eliminate myeloid leukemia
Thyroid cancer is the commonest endocrine malignancy, and typically affects younger adults. Despite low mortality rates, local recurrence is not uncommon and re-operative surgery can cause significant morbidity. We are studying genetic variants in thyroid transcription factors associated with thyroid cancer predisposition. Our work will determine the mechanism of this association, and provide new strategies for early diagnosis and prevention of thyroid cancer.
Cellular And Molecular Aspects Of Mammographic Density As A Predictor Of Breast Cancer Risk In Pseudo-orthotopic Mammatrophic Environment
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
High mammographic density (MD), or denser breast tissue on mammogram, is associated with greater breast cancer risk. Despite this, the basis for its increased risk is poorly understood. This study assesses the effect of high density breast tissue transferred from high risk women at time of mastectomy into tissue engineering chambers in mice. Changes in the connective tissue harvested from the chamber were examined with specialized imaging, laboratory stains and molecular analysis.
Dual Targeting Of The Androgen Receptor For Effective And Durable Control Of Lethal Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$946,177.00
Summary
Preventing binding of androgens to the androgen receptor is the mainstay treatment for advanced prostate cancer, but resistance inevitably develops and the disease becomes lethal. We will develop a new drug that targets a part of the androgen receptor unrelated to its androgen binding function to overcome resistance to current therapy. As this drug will be effective in all stages of prostate cancer, it has high potential to improve survival outcomes for men with prostate cancer.